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radiotherapy, e.g. for image guidance and target volume 
delineation. Compared to rigid registration, deformable 
image registration (DIR) is much more complex as the number 
of degrees of freedom in a typical DIR system exceeds the 
ten-thousands versus 6 for rigid registration. To make DIR 
tractable, registration systems therefore need to make a 
compromise between image similarity and smoothness of the 
deformation, attempting to find the &lsquo;smallest&rsquo; 
deformation that still optimizes the image similarity. This 
compromise is achieved by tuning a large amount of 
parameters, which is the &lsquo;trick of the trade&rsquo;. 
DIR is currently considered the most essential and most 
complicated component of on- and off-line adaptive 
radiotherapy and its validation is therefore essential. 
Validation programmes should look at technical, general, and 
patient-specific performance. Technical and general QA 
methods include 4D and anatomically realistic phantoms, 
natural and implanted fiducials, and manually placed 
landmarks, potentially using mathematical methods to 
account for observer variation. Visual verification is an 
essential patient specific form of QA, but an important 
caveat of deformable image registration is the inadequacy of 
visual validation to provide a final verdict on the registration 
accuracy, as completely different deformable registrations 
can result in the identical images. This is not a problem for 
descriptive tasks such as Hounsfield unit correction and 
autocontouring, where organ boundaries are sought, but is 
highly detrimental for quantitative tasks such as dose 
accumulation and treatment adaption around tumour 
boundaries where anatomical &ldquo;cell to cell&rdquo; 
correspondence is required. Another unsolved issue is that 
registration performance is poor around sliding tissues and 
anatomical changes in the patient and specific care should be 
taken with clinical decisions that depend on dose summation 
around such regions. I conclude that QA of deformable 
registration is complex, and that current algorithms lack 
biological and biomechanical knowledge. I believe that today 
it is therefore not safe to use them for dose-accumulation 
and treatment adaptation around shrinking tumours. 
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Introduction  
With the advent of Volumetric Modulated Arc Therapy 
(VMAT), Quality Assurance (QA) has evolved to a next step 
regarding complexity. Different parts of the linear 
accelerator (linac) move synchronously, resulting in a dose 
delivery that can be highly modulated in both space and 
time. In this lecture the practical aspects of QA are 
discussed, in particular focussed on VMAT.  
 
Machine QA  
Prior to implementing VMAT treatments in the clinic, the user 
should be familiar with the dynamic behaviour of the 
machine. In particular, features such as the lowest maximum 
leaf speed and the behaviour of the system under both dose 
rate changes and accelerations/decelerations of the gantry 
should be determined. Such machine characteristics need to 
be incorporated in the treatment planning system (TPS) to 
avoid devising undeliverable plans. To properly measure the 
dose delivered by the linac, the used measurement systems 
need to be dosimetrically accurate and have a high degree of 
spatial and temporal resolution. Usually different QA devices 
are needed to achieve this.  
 
Patient-specific QA  
Before a treatment plan can be delivered clinically, the 
medical physics expert (MPE) has to be convinced that the 
correspondence between calculated and measured dose 
delivery is adequate. This can be achieved by performing 
patient-specific QA, comparing the measured, integral dose 
with the computed one in a phantom. For this purpose, a 
high dosimetric accuracy combined with a high spatial 
resolution is required. Again, different measurement devices 
are in general needed to meet these demands. The 
interpretation of the differences between intended an 
delivered dose distribution, in terms of a gamma analysis, 
will be discussed. After gaining experience and confidence 
with a certain class solution for treatment plans, most MPE 
resort to using only point dose measurements or computer 
programs for independent validation. When and how to 
introduce such alternatives will be discussed in the lecture. 
The value of continuous patient-specific QA will also be 
addressed.  
 
Conclusion  
After the lecture, the participant should have a clear idea 
what type of detectors should be used for what purpose and 
how to optimise patient-specific QA in a busy clinical 
environment. 
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Lean Thinking originated from the manufacturing industry in 
Japan as a method of highly-efficient production. However, 
Lean Thinking is not confined to manufacturing and as a 
management strategy focused on improving processes, is 
applicable to any organisation. It is now well-established in 
the complex area of healthcare delivery. Lean Thinking has 
been described as “the dynamic, knowledge driven and 
customer-focused process through which all people in a 
defined enterprise work continuously to eliminate waste and 
to create value” (Rebentisch et al, 2004). For a healthcare 
organisation, it provides a patient-focused, systematic 
approach to identifying and eliminating waste (i.e. non-
value-added activities) through continuous improvement. The 
key principle of Lean is distinguishing value-added steps from 
non-value-added steps, and eliminating waste with the aim 
that eventually every step will add value to the overall 
process. 
The lean philosophy is not intended to reduce the number of 
employees working in the hospital. It seeks only to eliminate 
waste in tasks and processes so that time, materials, 
resources and procedures can be utilised as efficiently as 
possible with the aim of dedicating more time and effort to 
patient care without extra cost to the patient or healthcare 
organisation. 
Using case studies and real-life examples, this talk will 
introduce the lean concepts, principles and tools that 
contribute to improving efficiency, quality and patient safety 
in radiotherapy and healthcare. 
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Radiotherapy is along with surgery and chemotherapy one of 
the prime treatment modalities in cancer. It is applied in the 
primary, neoadjuvant as well as the adjuvant setting. 
Radiation techniques have rapidly evolved during the past 
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decade enabling the delivery of high radiation doses, 
reducing side-effects in tumour-adjacent normal tissues. 
While increasing local tumour control, current and future 
efforts ought to deal with microscopic disease at a distance 
of the primary tumour, ultimately responsible for disease-
progression. This talk will explores the possibility of bimodal 
treatment combining radiotherapy with immunotherapy. L19 
targets the extra domain B (ED-B) of fibronectin, a marker 
for tumor neoangiogenesis, and can be used as 
immunocytokine when coupled to IL2. We hypothesize that 
radiotherapy in combination with L19-IL2 provides an 
enhanced antitumor effect, which is dependent on ED-B 
expression.  
EXPERIMENTAL DESIGN: Mice were injected with syngeneic 
C51 colon carcinoma, Lewis lung carcinoma (LLC), or 4T1 
mammary carcinoma cells. Tumor growth delay, underlying 
immunologic parameters, and treatment toxicity were 
evaluated after single-dose local tumor irradiation and 
systemic administration of L19-IL2 or equimolar controls.  
RESULTS: ED-B expression was high, intermediate, and low 
for C51, LLC, and 4T1, respectively. The combination therapy 
showed (i) a long-lasting synergistic effect for the C51 model 
with 75% of tumors being cured, (ii) an additive effect for the 
LLC model, and (iii) no effect for the 4T1 model. The 
combination treatment resulted in a significantly increased 
cytotoxic (CD8(+)) T-cell population for both C51 and LLC. 
Depletion of CD8(+) T cells abolished the benefit of the 
combination therapy.  
CONCLUSIONS: These data provide the first evidence for an 
increased therapeutic potential by combining radiotherapy 
with L19-IL2 in ED-B-positive tumors. This new opportunity in 
cancer treatment will be investigated in a phase I clinical 
study for patients with an oligometastatic solid tumor 
(NCT02086721). An animation summarizing our results is 
available at 
https://www.youtube.com/watch?v=xHbwQuCTkRc .  
REFERENCE:. Zegers CM1, Rekers NH2, Quaden DH3, Lieuwes 
NG2, Yaromina A2, Germeraad WT4, Wieten L5, Biessen EA6, 
Boon L7, Neri D8, Troost EG2, Dubois LJ2, Lambin P2. 
Radiotherapy combined with the immunocytokine L19-IL2 
provides long-lasting antitumor effects. Clin Cancer Res. 2015 
Mar 1;21(5):1151-60. 
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For a number of tumour types there is increasing acceptance 
that cancer stem cells play an important role in tumour 
initiation and recurrence after treatment. In line with this 
model, increasing evidence indicates that cancer stem cells 
exhibit resistance to conventional cytotoxic agents. In the 
case of glioblastoma, an incurable primary brain tumour 
associated with dismal prognosis and devastating effects on 
quality of life, a series of influential publications have 
demonstrated that the radiation resistance of glioblastoma 
stem-like cells (GSC) is associated with constitutive 
upregulation of the DNA damage response (DDR).  
In this presentation I will outline the evidence supporting this 
model, and present new data that elucidates the relative 
contributions of DNA repair and cell cycle checkpoints to this 
phenotype. Subsequently I will investigate the effects of 
inhibiting various components of the DDR, alone and in 
combination, and discuss the potential clinical application of 
a number of promising new small molecule inhibitors. 
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Recent technological advances in DNA sequencing with 
greater speed and resolution at lower costs has provided new 
insights in cancer genetics. The next-generation sequencing 
(NGS) technology is tremendously facilitating the in-depth 
genome-wide search for genetic alterations which might 
significantly contribute to aggressive and/or treatment-
resistant phenotypes of cancers, thereby establishing the 
basis for improvement of cancer treatment. We hypothesized 
that NGS should also be useful for dissecting the molecular 
mechanisms of radioresistance in squamous cell carcinoma of 
the head and neck (HNSCC). 
We therefore applied the technology of targeted NGS to 
clinical samples from two multicenter studies of definitive 
and adjuvant cisplatin-based chemoradiation of locally 
advanced HNSCC. We evaluated whether by molecular 
profiling using targeted NGS it is possible to prospectively 
discriminate between patients who clearly benefit from 
chemoradiation and those with poor locoregional control and 
reduced overall survival after such treatment. Our studies 
could confirm previous reports of poor efficacy of 
radiotherapy in HNSCC tumors harboring TP53 mutations. For 
the first time, we identified additional mutations in other 
genes as predictive biomarkers of outcome after 
chemoradiation. 
The talk will summarize the results of NGS studies in HNSCC 
and other carcinoma models, thereby focusing on studies in 
which molecular mechanisms involved in radio-
/chemoresistance have been addressed. It will present 
unpublished results from functional studies in preclinical 
models in which we are evaluating the mode of interaction of 
distinct genetic variants with radio-/chemoresistance. 
Concepts of how to integrate the results from NGS into novel 
personalized treatment strategies for HNSCC will be 
discussed. 
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Massive parallel sequencing technologies (also: next 
generation sequencing) have revolutionized our 
understanding of the genomic and transcriptional makeup of 
malignomas. Aided by equally impressive developments in 
sequencing- and chip-based epigenetic tumor profiling and 
developments in mass spectrometry which allow for a 
comprehensive proteomic and metabolomic profiling we are 
now able to draw fairly comprehensive multi –omics 
landscapes of individual tumors both from tissue but 
increasingly also from blood or circulating tumor cells. 
However, many issues remain still challenging when it comes 
to a translation of these findings into a potential clinical 
outreach. This includes matters of tumor heterogeneity 
specifically with respect to tumor evolution in the metastatic 
setting as well as under therapeutic pressure. Other widely 
unresolved issues include the usefulness of identified drivers 
as novel targets for therapy or as predictive biomarkers and 
strategies to implement broad high throughput genomic 
testing into individualized patient care. Specifically the 
latter issue will decide which of these multi–omics 
technologies will take the step from tools merely for 
biological research profiling to advanced and modern routine 
clinical care. 
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Gene expression profiles hold great promises for PRO 
(Personalized Radiation Oncology), yet very few - if any - are 
implemented in routine clinical practice and used as 
predictive biomarkers for treatment decisions in radiation 
oncology. 
